

**REMARKS**

As a result of the foregoing amendments, claim 1 has been amended to incorporate all the limitations of canceled claim 2, and claim 3 has been rewritten in independent form. Claims 2, 4 and 5 have been canceled. New claims 13-18 have been added to mirror claims 6-9, 11 and 12, but depend on newly independent claim 3. The phrase "peptide/protein" has been replaced throughout the claims with the term "polypeptide", with an intent to clarify, and not to modify the scope of the claims in any way. Various typographical, grammar and antecedent errors have been corrected, including those objected to in the Office Action. No new matter has been entered by this amendment. Claims 1, 3, and 6-18 are now pending. Reconsideration and withdrawal of all rejections of the pending claims are respectfully requested.

All the prior art rejections of the Office Action of October 6, 2005, have been overcome by this amendment. On page 6 of the Office Action, the subject matter of original claims 2, 3 and 10 are stated to be clear of the cited art. As amended above, each of the pending claims now includes all the limitations of either original claim 2 or original claim 3. Accordingly, the prior art rejections should be withdrawn.

This application is in condition for allowance.

Respectfully submitted,



F. Aaron Dubberley  
Attorney for Applicant(s)  
Reg. No. 41,001

Akzo Nobel Inc.  
Intellectual Property Department  
7 Livingstone Avenue  
Dobbs Ferry, NY 10522-3408  
Tel No.: (973) 325-4542